The Beauty Health Co (NASDAQ:SKIN) is set to release its Q1 2025 earnings on May 8, 2025. The consensus estimate for Q1 2025 revenue is $63.81 million, and the earnings are expected to come in at -$0.13 per share. The full year 2025’s revenue is expected to be $288.46 million, and the earnings are expected to be -$0.29 per share. More detailed estimate data can be found on the Forecast page.
Over the past 90 days, revenue estimates for The Beauty Health Co (NASDAQ:SKIN) have declined from $334.08 million to $288.46 million for the full year 2025 and from $375.55 million to $309.18 million for 2026. Earnings estimates have also declined, from -$0.27 per share to -$0.29 per share for 2025 and from -$0.19 per share to -$0.20 per share for 2026.
In the previous quarter ending December 31, 2024, The Beauty Health Co’s (NASDAQ:SKIN) actual revenue was $83.50 million, which beat analysts’ revenue expectations of $77.39 million by 7.90%. The actual earnings were -$0.08 per share, exceeding analysts’ expectations of -$0.108 per share by 25.93%. After releasing the results, The Beauty Health Co (NASDAQ:SKIN) saw a decrease of 5.63% in one day.
Based on the one-year price targets offered by 6 analysts, the average target price for The Beauty Health Co (NASDAQ:SKIN) is $1.58, with a high estimate of $2.00 and a low estimate of $1.00. The average target implies an upside of 49.29% from the current price of $1.06.
Based on GuruFocus estimates, the estimated GF Value for The Beauty Health Co (NASDAQ:SKIN) in one year is $4.97, suggesting an upside of 371.09% from the current price of $1.06.
Based on the consensus recommendation from 9 brokerage firms, The Beauty Health Co’s (NASDAQ:SKIN) average brokerage recommendation is currently 3.3, indicating a “Hold” status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
